Intravesical Bacillus Calmette-Guérin instillation therapy after transurethral resection of bladder tumor is considered as the most effective treatment for prophylaxis against the recurrence of high-risk, non-muscle…
Information on the effect of Bacillus Calmette-Guerin (BCG) vaccine in tuberculosis (TB) drug resistance will be useful in planning the application of the BCG vaccine. The aim of this
Bacillus Calmette-Guerin (BCG) vaccine, which is a live attenuated strain derived from Mycobacterium bovis, is widely administrated for newborn infants in the world for preventing disseminated and meningeal tuberculosis
Intravesical bacillus Calmette-Guerin (BCG) instillation is a commonly used treatment for urothelial bladder carcinoma. Soft tissue manifestation of Mycobacterium tuberculosis ( M. tuberculosis) following administration…
Introduction: Non-specific immunotherapy consisting of intravesical instillation of Bacillus Calmette-Guerin (BCG) is currently the best available treatment to prevent non- muscle-invasive bladder tumor recurrence and…
immune response induced by a mixture of polysaccharide and nucleic acid extracted from Bacillus Calmette-Guerin (BCG) was evaluated in chickens inoculated with infectious bursal disease virus (IBDV) vaccine. After
Bacillus Calmette-Guérin (BCG) immunotherapy flops in up to 40% of patients with high-risk non-muscle obtrusive bladder disease (NMIBC), with these disappointments happening inside the initial a half
with this disease in Pakistan. Vaccination is the way to prevent disease occurrence. Bacillus Calmette-Guerin (BCG) is the only licensed vaccine against TB throughout the world. However, protective immunity
humans, regulatory properties of L. alata extract (LAE) was studied using a Bacillus Calmette-Guerin- Lipopolysaccharide (BCG-LPS) induced immune liver injury model in mice. Quantificational analysis of LAE indicated
acute TB because morbidity and mortality are very high. Evidence suggests that Bacillus Calmette-Guerin (BCG) vaccination reduces the risk of disseminated TB however we present a case report
tumours, our research group generated a recombinant MUC1-MBP fusion protein combined with Bacillus Calmette-Guerin (MUC1-MBP/BCG) anti-tumour vaccine, the repeated animal experiments demonstrated that MUC1
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.